Flamingo Therapeutics, an RNA-focused digital therapeutics company, has added a new member to its board of directors, Dr. Ezra Cohen.
Flamingo manufactures RNA therapies for oncology and is backed by investors including Andera Partners, Bpifrance Large Venture, Perceptive Advisors, Sphera, and VIB.
Dr. Cohen has a background in drug development, particularly for head and neck cancer.
“Flamingo's science and team are very impressive and I am excited to join the board following the recent launch of several important oncology clinical studies. I believe we are uniquely positioned to improve the state of head and neck care, and I look forward to working with the team to provide new treatment options for patients,'' Dr. Cohen said in a statement.
life science software company synthesis announced the appointment of Willem Barart as the new Chairman of the Board. Mr. Baralt joined the company in February.
Synthace supports R&D scientists through automation across multiple stages, including experimental design, simulation, and the creation of comprehensive digital records.
Baralt has served on the boards of several medical and charitable organizations.She recently worked for a mobile dialysis machine manufacturer. Quanta Dialysis TechnologyWhich Secures $245 million in Series D funding in 2021.
“I am truly honored to join the Synthace team at this time as we aim to transform the life sciences R&D landscape.Synthace uses a digital experimentation platform to help scientists design experiments that were previously impossible. Synthace's technology is key to enabling the R&D lab of the future and enabling customers to realize significant time and cost savings while developing new treatments. ” Balart said in a statement.